RT Journal Article
SR Electronic
T1 Sudden Death and Cardiac Arrythmia With Lamotrigine
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP e1748
OP e1760
DO 10.1212/WNL.0000000000200164
VO 98
IS 17
A1 Bunschoten, Johanna W.
A1 Husein, Nafisa
A1 Devinsky, Orrin
A1 French, Jacqueline A.
A1 Sander, Josemir W.
A1 Thijs, Roland D.
A1 Keezer, Mark R.
YR 2022
UL http://n.neurology.org/content/98/17/e1748.abstract
AB Background and Objectives A recent Food and Drug Administration warning concerning an arrhythmogenic potential of lamotrigine created concern in the neurologic community. This warning was based on in vitro studies, but no clinically relevant risk was considered. This rapid systematic review aims to elucidate the risk of lamotrigine on sudden death or ECG abnormalities.Methods We conducted a systematic search of Ovid Medline and Ovid Embase, including randomized controlled trials and observational studies and studies of people with or without epilepsy, with the outcome measures sudden unexpected death in epilepsy (SUDEP) or sudden cardiac death as well as the development or worsening of ECG abnormalities. We evaluated the sudden death definitions used in all included studies, as some could have used unclear or overlapping definitions. We used the American Academy of Neurology risk of bias tool to evaluate the class of evidence and the GRADE approach to evaluate our confidence in the evidence.Results We included 26 studies with 24,962 participants, of whom 2,326 used lamotrigine. Twelve studies showed no significant risk of SUDEP for lamotrigine users. One study reporting on sudden cardiac death and 3 studies with unclear sudden death definitions did not report an elevated risk of death in lamotrigine users compared to controls. In 10 studies reporting on ECG measures, there was no statistically significant increased risk among lamotrigine users except in 2 studies. These 2 studies reported either “slight increases” in PR interval or an increased PQ interval that the primary study authors believed to be related to structural cardiac differences rather than an effect of lamotrigine. One study was rated Class II; all others were Class III or IV. We had very low confidence in the evidence following the GRADE assessment. None of the studies examined the risk of lamotrigine in people with preexisting cardiac conditions.Discussion There is insufficient evidence to support or refute that lamotrigine is associated with sudden death or ECG changes in people with or without epilepsy as compared to antiseizure medication or placebo, due to the high risk of bias in most studies and low precision and inconsistency in the reported results.AAN=American Academy of Neurology; ASM=antiseizure medication; FDA=Food and Drug Administration; GRADE=Grading of Recommendations Assessment, Development and Evaluation; HRV=heart rate variability; SUDEP=sudden unexpected death in epilepsy